Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C | Zendy

Jihane N. Benhammou | Zendy; Andrew M. Moon | Zendy; Joseph R. Pisegna | Zendy; Feng Su | Zendy; Philip Vutien | Zendy; Cynthia A. Moylan | Zendy; George N. Ioannou | Zendy

Open Access

Nonalcoholic Fatty Liver Disease Risk Factors Affect Liver-Related Outcomes After Direct-Acting Antiviral Treatment for Hepatitis C

Author(s) -

Jihane N. Benhammou,

Andrew M. Moon,

Joseph R. Pisegna,

Feng Su,

Philip Vutien,

Cynthia A. Moylan,

George N. Ioannou

Publication year - 2020

Publication title -

digestive diseases and sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.14

H-Index - 124

eISSN - 1573-2568

pISSN - 0163-2116

DOI - 10.1007/s10620-020-06457-2

Subject(s) - medicine , cirrhosis , gastroenterology , diabetes mellitus , hepatitis c , nonalcoholic fatty liver disease , body mass index , decompensation , hepatocellular carcinoma , liver disease , type 2 diabetes , fatty liver , disease , endocrinology

In hepatitis C (HCV) patients, obesity and/or diabetes may increase the risk of liver-related outcomes. We aimed to determine whether diabetes and/or obesity are associated with adverse outcomes in direct-acting antiviral (DAA)-treated HCV patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research